ArticleRSC advances2026
Synthesis and evaluation of resveratrol-cerium modified hydroxyapatite for enhanced bone repair scaffolds.
Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metal-phenolic networks (MPNs) are a category of amorphous coordination network materials formed by metal ions and phenolic ligands. They can be integrated into matrix composites to significantly enhance the overall functionality of the composites. In this study, to leverage the anti-inflammatory, antibacterial, and osteogenic properties of resveratrol (Res) and cerium (Ce), an innovative Res-Ce MPN was synthesized to modify hydroxyapatite (HA) nanoparticles. These Res-Ce/HA nanoparticles were then blended with polycaprolactone (PCL) to fabricate 3D-printed bone repair scaffolds. The results showed that the composite scaffold containing 10% Res-Ce/HA nanoparticles (PCL@10Res-Ce/HA) exhibited improved antibacterial activity.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.